Replies to post #14258 on BioSante Pharmaceuticals, Inc. (BPAX)

[Just the facts maam]

I was wondering if the CV benefit and testosterone replenishment to pre-menopausal levels can offset the lack of superiority over placebo. I noticed that the placebo results were much stronger then those faced by the Intrinsa trials, it seems many companies are facing this type of problem. It then comes down to clearly identifying a Intent to Treat audience in the subset data and/or accounting for the extremely high placebo results. I think Nutsyprofessor indicated the exclusion criteria in Intrinsa was much more restrictive then the Bloom trials for Libigel and he believed it was intentionally set up to fail, to indicate that it should only be used for it's intended purpose. In light of the results and comparisons with Intrinsa's trails, this seems to make sense.